Tianshu Liu

Fudan University, Zhongshan Hospital, Department of Oncology

China

Fudan University - Department of Medical Oncology

China

Fudan University - Center of Evidence-based Medicine

Shanghai

China

SCHOLARLY PAPERS

3

DOWNLOADS

31

SSRN CITATIONS

0

CROSSREF CITATIONS

0

Scholarly Papers (3)

1.

Chidamide Plus Exemestane for Postmenopausal Patients with Hormone-Receptor-Positive Advanced Breast Cancer (ACE Study): A Randomised, Double-Blind, Placebo-Controlled Phase 3 Trial

The Lancet Oncology, VOLUME 20, ISSUE 6, P806-815, JUNE 01, 2019, https://doi.org/10.1016/S1470-2045(19)30164-0
Number of pages: 90 Posted: 05 Feb 2019
Chinese PLA General Hospital, Fifth Medical Centre, Jilin University (JLU) - First Affiliated Hospital, Fudan University - Shanghai Cancer Center (FUSCC), Harbin Medical University - Cancer Hospital, Liaoning Cancer Hospital & Institute, Zhengzhou University - Henan Cancer Hospital, Sun Yat-Sen University (SYSU) - Cancer Center, Central South University - Hunan Cancer Hospital, Jiangsu Province People's Hospital, Tumour Hospital of Hebei Province, Tianjin Medical University, Jilin Cancer Hospital, Anhui Provincial Hospital, Shandong University - Jinan Central Hospital, Third Hospital of Nanchang, Beijing Cancer Hospital, Anhui Medical University - First Affiliated Hospital, Jiangsu Cancer Hospital - Department of Medical Oncology, Zhejiang Cancer Hospital, Peking University - Shenzhen Hospital, Fudan University, Zhongshan Hospital, Department of Oncology, Cangzhou Central Hospital, Northwestern University - Feinberg School of Medicine, Chipscreen Biosciences Ltd and Chipscreen Biosciences Ltd
Downloads 18 (579,467)

Abstract:

Loading...

Chidamide; Histone deacetylase inhibitor; Exemestane; Hormonereceptor- positive; Advanced breast cancer; Phase 3 trial

2.

HnRNPR/CCNB1/CENPF Axis Contributes to Gastric Cancer Proliferation and Metastasis

Number of pages: 36 Posted: 21 May 2019
Fudan University, Peking University, Fudan University - Department of Medical Oncology, Fudan University - Department of Medical Oncology, Fudan University - Department of Medical Oncology, Fudan University - Department of Medical Oncology, Fudan University - Department of Medical Oncology, Fudan University - Department of Medical Oncology, Fudan University - Zhongshan Hospital and Fudan University, Zhongshan Hospital, Department of Oncology
Downloads 9 (640,344)

Abstract:

Loading...

HnRNPR, Gastric cancer, RNA binding protein, CCNB1, CENPF

3.

Bevacizumab Plus Chemotherapy versus Chemotherapy Alone As First-Line Treatment for Patients with RAS Mutant Unresectable Colorectal Liver-Limited Metastases: The BECOME Single Center Randomized Control Trial

Number of pages: 43 Posted: 29 Dec 2019
Fudan University - Department of General Surgery, Fudan University - Department of General Surgery, Fudan University - Department of Liver Surgery and Transplantation, Fudan University - Department of General Surgery, Fudan University - Department of General Surgery, Fudan University - Department of General Surgery, Fudan University - Department of Liver Surgery and Transplantation, Fudan University - Department of Radiology, Fudan University, Zhongshan Hospital, Department of Oncology, Fudan University, Zhongshan Hospital, Department of Oncology and Fudan University - Department of General Surgery
Downloads 4 (676,675)

Abstract:

Loading...

Bevacizumab; RAS mutant; unresectable; colorectal liver-limited metastases